Clinical Trial Update: Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and efficacy study of TPI-287 in neuroblastoma and medulloblastoma was terminated. Results were posted on 2016-10-28.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma
• Neuroblastoma

Drugs mentioned

• TPI-287

Snippet

Sponsor: Giselle Sholler | Conditions: Neuroblastoma, Medulloblastoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-10-28